Cyclerion Therapeutics (CYCN) Share-based Compensation (2018 - 2025)
Cyclerion Therapeutics (CYCN) recorded quarterly Share-based Compensation of $118000.0 in Q3 2025, up 3.51% quarter-over-quarter from $114000.0 in Q2 2025, and down 14.49% on a YoY basis from $138000.0 in Q3 2024.
Cyclerion Therapeutics (CYCN) Share-based Compensation (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $118000.0 for Q3 2025.
- In Q3 2025, Share-based Compensation fell 14.49% year-over-year to $118000.0; the TTM figure through Sep 2025 stood at $468000.0 (down 22.77% YoY), while the FY2024 annual figure was $625000.0, down 41.42% from the prior year.
- Share-based Compensation was $118000.0 for Q3 2025 at Cyclerion Therapeutics, up from $114000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.5 million in Q4 2021 to a low of $103000.0 in Q4 2023.
- Historically, Share-based Compensation has averaged $942157.9 across 5 years, with a median of $379000.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation sank 90.84% in 2023, then advanced 18.45% in 2024.
- A 5-year view of Share-based Compensation shows it stood at $2.5 million in 2021, then plunged by 55.87% to $1.1 million in 2022, then tumbled by 90.84% to $103000.0 in 2023, then rose by 18.45% to $122000.0 in 2024, then dropped by 3.28% to $118000.0 in 2025.
- The last three Share-based Compensation figures came in at $118000.0 (Q3 2025), $114000.0 (Q2 2025), and $114000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 26.47 Mn |
| 10 | Cyclerion Therapeutics | 11.50 Mn | 8.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 118,000.00 |
| Sep 30, 2025 | 118,000.00 |
| Jun 30, 2025 | 114,000.00 |
| Jun 30, 2025 | 114,000.00 |
| Mar 31, 2025 | 114,000.00 |
| Mar 31, 2025 | 114,000.00 |
| Dec 31, 2024 | 122,000.00 |
| Dec 31, 2024 | 122,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 184,000.00 |
| Mar 31, 2024 | 181,000.00 |
| Mar 31, 2024 | 181,000.00 |
| Dec 31, 2023 | 103,000.00 |
| Dec 31, 2023 | 103,000.00 |
| Sep 30, 2023 | 159,000.00 |
| Sep 30, 2023 | 159,000.00 |
| Jun 30, 2023 | 379,000.00 |
| Jun 30, 2023 | 379,000.00 |